Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Payables (2020 - 2025)

Tango Therapeutics has reported Payables over the past 6 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Payables at $1.2 million for Q4 2025, down 26.17% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (down 26.17% YoY), and the annual figure for FY2025 was $1.2 million, down 26.17%.
  • Payables for Q4 2025 was $1.2 million at Tango Therapeutics, down from $2.2 million in the prior quarter.
  • Over the last five years, Payables for TNGX hit a ceiling of $6.3 million in Q3 2022 and a floor of $26279.0 in Q2 2021.
  • Median Payables over the past 5 years was $3.0 million (2021), compared with a mean of $2.9 million.
  • Biggest five-year swings in Payables: skyrocketed 60093.61% in 2021 and later plummeted 77.84% in 2024.
  • Tango Therapeutics' Payables stood at $3.2 million in 2021, then soared by 38.03% to $4.5 million in 2022, then plummeted by 37.46% to $2.8 million in 2023, then plummeted by 42.51% to $1.6 million in 2024, then dropped by 26.17% to $1.2 million in 2025.
  • The last three reported values for Payables were $1.2 million (Q4 2025), $2.2 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.